Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
Eniware, LLC provides portable, power-independent medical instrument sterilization...
Eniware, LLC provides portable, power-independe...
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision med...
MyoKardia is a clinical-stage biopharmaceutical...
Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...
Aquestive Therapeutics is a specialty pharmaceu...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Join the National Investor Network and get the latest information with your interests in mind.